{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:31:29Z","timestamp":1784907089193,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Science and Health Joint Traditional Chinese Medicine Project","award":["2025ZYYB017"],"award-info":[{"award-number":["2025ZYYB017"]}]},{"name":"Chongqing University Jiangjin Hospital Internal Cultivation Project","award":["2024LCXM002"],"award-info":[{"award-number":["2024LCXM002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02553-9","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T10:17:54Z","timestamp":1746872274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion chemotherapy of RALOX versus FOLFOX for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score-matching cohort study"],"prefix":"10.1007","volume":"16","author":[{"given":"Hao-yang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-quan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-hua","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-guo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"20","key":"2553_CR1","doi-asserted-by":"publisher","first-page":"33911","DOI":"10.18632\/oncotarget.15411","volume":"8","author":"J-F Jiang","year":"2017","unstructured":"Jiang J-F, Lao Y-C, Yuan B-H, Yin J, Liu X, Chen L, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8(20):33911\u201321. https:\/\/doi.org\/10.18632\/oncotarget.15411.","journal-title":"Oncotarget"},{"key":"2553_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.05.009","author":"Z Zong-ming","year":"2015","unstructured":"Zong-ming Z, Lai E, Chong Z, Hongwei Y, Zhuo L, Bo-jiang W, et al. The strategies for treating primary hepatocellular carcinoma with\u00a0port al vein tumor thrombus. Int J Surg. 2015. https:\/\/doi.org\/10.1016\/j.ijsu.2015.05.009.","journal-title":"Int J Surg"},{"key":"2553_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635731","author":"F Luo","year":"2021","unstructured":"Luo F, Li M, Ding J, Zheng S. The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.635731.","journal-title":"Front Oncol"},{"issue":"6","key":"2553_CR4","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/hep.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365. https:\/\/doi.org\/10.1097\/hep.0000000000000466. (Epub 2023\/05\/18).","journal-title":"Hepatology"},{"issue":"8","key":"2553_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070. (Epub 2022\/08\/01).","journal-title":"NEJM Evid."},{"issue":"20","key":"2553_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745. (Epub 2020\/05\/14).","journal-title":"N Engl J Med"},{"key":"2553_CR7","doi-asserted-by":"publisher","unstructured":"Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major p ortal vein tumor thrombus Surgery today. 2014; 44(2):219\u201326. https:\/\/doi.org\/10.1007\/s00595-013-0585-6.","DOI":"10.1007\/s00595-013-0585-6"},{"issue":"1","key":"2553_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14218\/jcth.2021.00179","volume":"10","author":"Z-J Deng","year":"2021","unstructured":"Deng Z-J, Li L, Teng Y-X, Zhang Y-Q, Zhang Y-X, Liu H-T, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Translat Hepatol. 2021;10(1):147\u201358. https:\/\/doi.org\/10.14218\/jcth.2021.00179.","journal-title":"J Clin Translat Hepatol."},{"issue":"5","key":"2553_CR9","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.18632\/oncotarget.12817","volume":"8","author":"C Shuqun","year":"2017","unstructured":"Shuqun C, Minshan C, Jianqiang C. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edit ion. Oncotarget. 2017;8(5):8867\u201376. https:\/\/doi.org\/10.18632\/oncotarget.12817.","journal-title":"Oncotarget"},{"key":"2553_CR10","doi-asserted-by":"publisher","unstructured":"Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, et al. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combin ed with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcino ma Patients with Major Portal Vein Tumor Thrombosis. Oncology. 2018; 94(4): 215\u201322. https:\/\/doi.org\/10.1159\/000486483.","DOI":"10.1159\/000486483"},{"key":"2553_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15010","author":"L Miao","year":"2020","unstructured":"Miao L, Jun-lin S, Tong M, Yang W, Zhongjun W, Ai S. A systematic review of hepatic arterial infusion chemotherapy versus s orafenib in patients with hepatocellular carcinoma with portal vein tu mor thrombosis. J Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1111\/jgh.15010.","journal-title":"J Gastroenterol Hepatol"},{"key":"2553_CR12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S126181","author":"Z Qianqian","year":"2016","unstructured":"Qianqian Z, Kunli Z, Jinbo Y, Zhonghua Q, Shu-mei J, Xiao-qing X, et al. Comparison of intra-arterial chemoembolization with and without radiot herapy for advanced hepatocellular carcinoma with portal vein tumor th rombosis: a meta-analysis. Therapeut Clin Risk Manage. 2016. https:\/\/doi.org\/10.2147\/TCRM.S126181.","journal-title":"Therapeut Clin Risk Manage"},{"key":"2553_CR13","doi-asserted-by":"publisher","DOI":"10.1159\/000513706","author":"K Yumi","year":"2021","unstructured":"Yumi K, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Kensuke N, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the Ma in trunk or bilobar of the portal vein. Liver cancer. 2021. https:\/\/doi.org\/10.1159\/000513706.","journal-title":"Liver cancer."},{"key":"2553_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.05.006","author":"RC Sae","year":"2015","unstructured":"Sae RC, Jin HK, Yoon HK, Ko GY, Gwon DI, Shin JH, Song HY, Ko HK, Yoon SM, et al. Combined cisplatin-based chemoembolization and radiation therapy for H epatocellular Carcinoma invading the main portal vein. J Vasc Int Radiol. 2015. https:\/\/doi.org\/10.1016\/j.jvir.2015.05.006.","journal-title":"J Vasc Int Radiol."},{"key":"2553_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04620-1","author":"HY Tan","year":"2024","unstructured":"Tan HY, Liu SQ, Zheng JL, Liu HY, Liu YH, Dai GH, et al. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. Abdom radiol. 2024. https:\/\/doi.org\/10.1007\/s00261-024-04620-1. (Epub 2024\/10\/11).","journal-title":"Abdom radiol."},{"issue":"1","key":"2553_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao M, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int. 2024;18(1):4\u201331. https:\/\/doi.org\/10.1007\/s12072-023-10599-6. (Epub 2023\/10\/21).","journal-title":"Hepatol Int"},{"issue":"1","key":"2553_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12916-022-02608-6","volume":"20","author":"Z Lai","year":"2022","unstructured":"Lai Z, Huang Y, Wen D, Lin X, Kan A, Li Q, et al. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Med. 2022;20(1):415. https:\/\/doi.org\/10.1186\/s12916-022-02608-6. (Epub 2022\/11\/01).","journal-title":"BMC Med"},{"key":"2553_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111019","author":"M Zang","year":"2023","unstructured":"Zang M, Xiaoyun H, Guosheng Y, Rong L, Wenli L, Huajin P, et al. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxali platin, 5-fluorouracil and leucovorin for intermediate and advanced he patocellular carcinoma: a retrospective study. Int Immunopharmacol. 2023. https:\/\/doi.org\/10.1016\/j.intimp.2023.111019.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"2553_CR19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/jso.27023","volume":"126","author":"S Chen","year":"2022","unstructured":"Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: a propensity score-matching cohort study. J Surg Oncol. 2022;126(7):1205\u201314. https:\/\/doi.org\/10.1002\/jso.27023. (Epub 2022\/07\/21).","journal-title":"J Surg Oncol"},{"key":"2553_CR20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16298","author":"W Cui","year":"2017","unstructured":"Cui W, Fan W, Zhang Q, Wen J, Huang Y, Yang J, Li J, Wang Y, et al. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxalipla tin versus 5-fluorouracil plus oxaliplatin. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.16298.","journal-title":"Oncotarget"},{"issue":"6","key":"2553_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2015;1(6):756\u201365. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2189. (Epub 2015\/07\/17).","journal-title":"JAMA Oncol"},{"issue":"2","key":"2553_CR22","doi-asserted-by":"publisher","first-page":"Cd012244","DOI":"10.1002\/14651858.CD012244.pub2","volume":"2","author":"L Lu","year":"2019","unstructured":"Lu L, Zeng J, Wen Z, Tang C, Xu N. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev. 2019;2(2):Cd012244. https:\/\/doi.org\/10.1002\/14651858.CD012244.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2553_CR23","doi-asserted-by":"publisher","unstructured":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599\u2013641. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.021. Epub 2012\/03\/20","DOI":"10.1016\/j.ejca.2011.12.021"},{"issue":"2","key":"2553_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026. (Epub 2008\/12\/23).","journal-title":"Eur J Cancer"},{"key":"2553_CR25","doi-asserted-by":"publisher","unstructured":"Gilbert A, Piccinin C, Velikova G, Groenvold M, Kuli\u015b D, Blazeby JM, et al. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events. J Clin Oncol. 2022;40(32):3770\u201380. Epub 2022\/08\/17. https:\/\/doi.org\/10.1200\/jco.21.02017. PubMed PMID: 35973158; PubMed Central PMCID: PMCPMC9649281 or Advisory Role: Roche UK, Eisai, Novartis, Sanofi Speakers' Bureau: Novartis Research Funding: Pfizer (Inst), IQVIA (Inst) Travel, Accommodations, Expenses: Roche UK, Novartis, Eisai Other Relationship: University of Leeds No other potential conflicts of interest were reported.","DOI":"10.1200\/jco.21.02017"},{"issue":"5","key":"2553_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12032-023-02012-x","volume":"40","author":"F Long","year":"2023","unstructured":"Long F, Chen S, Li R, Lin Y, Han J, Guo J, et al. Efficacy and safety of HAIC alone vs HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma. Med Oncol. 2023;40(5):147. https:\/\/doi.org\/10.1007\/s12032-023-02012-x.","journal-title":"Med Oncol"},{"key":"2553_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.005. (Epub 2022\/08\/19).","journal-title":"Eur J Cancer"},{"key":"2553_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58101343","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zheng S, Zhang Z, Chen G, Chen X, Zheng T, et al. Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed as an alternative option in advanced hepatocellular carcinoma patients with failure of, or unsuitability for transarterial chemoembolization. Medicina. 2022. https:\/\/doi.org\/10.3390\/medicina58101343.","journal-title":"Medicina"},{"key":"2553_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02053-6","author":"X Tu","year":"2024","unstructured":"Tu X, Zhang W, Li S, He Q, Li Y. Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens. Eur J Med Res. 2024. https:\/\/doi.org\/10.1186\/s40001-024-02053-6.","journal-title":"Eur J Med Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02553-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T10:17:55Z","timestamp":1746872275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02553-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02553-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This study adhered to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Chongqing University Jiangjin Hospital (KY20240812-001). This study was registered in the Chinese Clinical Trial Registry (ChiCTR2500095127). The patient's informed consent form before treatment complied with the requirements of the Institutional Review Committee of Chongqing University Jiangjin Hospital. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"717"}}